Welcome to our dedicated page for Regencell Bioscience Holdings news (Ticker: RGC), a resource for investors and traders seeking the latest updates and insights on Regencell Bioscience Holdings stock.
Regencell Bioscience Holdings Limited develops Traditional Chinese Medicine formulae for neurocognitive disorders and infectious diseases. News about RGC centers on its early-stage bioscience programs for ADHD and ASD, including personalized and standardized TCM formulae, assessment methods such as SKATBT-A3, and efficacy trial updates using parent-reported scoring systems.
Company updates also cover the RGC-COV19 oral liquid formulation and EARTH efficacy trial analyses for mild to moderate COVID-19 symptoms. Other recurring developments include ordinary-share ownership disclosures, lock-up undertakings, board appointments and governance changes tied to Regencell’s public-company status.
Regencell Bioscience Holdings Limited (NASDAQ:RGC) announced that its underwriter exercised an option to purchase 325,000 additional ordinary shares at $9.50 each as part of its initial public offering (IPO). The total gross proceeds of the IPO, including this option, reached $24,937,500, before expenses. Funds will be allocated to research studies, product development, staff salaries, and corporate expenses. The company specializes in Traditional Chinese Medicine for neurocognitive disorders like ADHD and ASD, aiming to commercialize liquid-based TCM formulae for these conditions.
Regencell Bioscience Holdings Limited (NASDAQ: RGC) has announced significant milestones and future plans in a letter from CEO Yat-Gai Au. The company focuses on Traditional Chinese Medicine (TCM) for treating neurocognitive disorders like ADHD and ASD. Regencell raised approximately $19.3 million from its IPO on July 16, 2021, aimed at funding further research and development. Following a successful initial study showing reduced symptoms in ADHD and ASD patients, a second study is set to begin next month, with 100 participants. The outcome will support future proprietary medicine registration.
Regencell Bioscience Holdings Limited (NASDAQ:RGC) announced the closing of its initial public offering, raising $21.9 million by offering 2,300,000 ordinary shares at $9.50 per share. The company has also granted underwriters a 45-day option for an additional 345,000 shares. Proceeds will fund a second research study, product development, salaries, and other operational costs. Registered with the SEC, the offering enables Regencell to advance its focus on Traditional Chinese Medicine for ADHD and ASD treatments.
Regencell Bioscience Holdings Limited (NASDAQ:RGC) announced its initial public offering of 2,300,000 ordinary shares priced at $9.50 each, expecting gross proceeds of about $21.9 million. The shares will trade on the Nasdaq Capital Market starting July 16, 2021. Proceeds will fund research initiatives, TCM development, staff costs, and general corporate purposes. The offering is set to close around July 20, 2021, pending customary conditions. Maxim Group LLC is the sole book-running manager for the offering.